TRACK (2026) — Trial Summary

TRACK (2026): Randomized, double-blind, placebo-controlled trial at 90 centers in 12 countries of rivaroxaban 2.5 mg twice daily versus placebo in adults with CKD stage 4 or 5 or dialysis-dependent kidney failure plus elevated cardiovascular risk (prior CAD/PAD, nonhemorrhagic nonlacunar stroke, dia

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.